Literature DB >> 10839724

Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.

J T Grayston1.   

Abstract

Attributes of Chlamydia pneumoniae of potential importance to a relationship with atherosclerosis are described. Among these are that C. pneumoniae is not new. It is unique. It is a pathogen with which everyone is infected, and it is difficult to treat. It causes immunopathology, myocarditis, and endocarditis and chronicity is a hallmark of Chlamydia infection. Current knowledge of the relation of C. pneumoniae and atherosclerosis comes from observational (e.g., seroepidemiology and tissue studies) and experimental studies. The limitations of the serologic studies of chronic infection are noted as is the conclusive demonstration of an association of C. pneumoniae and atherosclerosis by the repeated and frequent finding of the organism in atherosclerotic tissue. Experimental studies are needed to determine if the association is causal. Such studies should include animal models, basic mechanisms, and secondary prevention antibiotic treatment trials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839724     DOI: 10.1086/315596

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  73 in total

1.  cDNA array analysis of altered gene expression in human endothelial cells in response to Chlamydia pneumoniae infection.

Authors:  B K Coombes; J B Mahony
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Epithelial cells infected with Chlamydophila pneumoniae (Chlamydia pneumoniae) are resistant to apoptosis.

Authors:  K Rajalingam; H Al-Younes; A Müller; T F Meyer; A J Szczepek; T Rudel
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 3.  Sodium ion cycle in bacterial pathogens: evidence from cross-genome comparisons.

Authors:  C C Häse; N D Fedorova; M Y Galperin; P A Dibrov
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

4.  Chlamydia pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors required for [correction of factors is required for] major histocompatibility complex antigen expression.

Authors:  Peiyi Fan; Feng Dong; Yanqing Huang; Guangming Zhong
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Genomic approach for analysis of surface proteins in Chlamydia pneumoniae.

Authors:  Silvia Montigiani; Fabiana Falugi; Maria Scarselli; Oretta Finco; Roberto Petracca; Giuliano Galli; Massimo Mariani; Roberto Manetti; Mauro Agnusdei; Roberto Cevenini; Manuela Donati; Renzo Nogarotto; Nathalie Norais; Ignazio Garaguso; Sandra Nuti; Giulietta Saletti; Domenico Rosa; Giulio Ratti; Guido Grandi
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 6.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

7.  Temporal expression of type III secretion genes of Chlamydia pneumoniae.

Authors:  Anatoly Slepenkin; Vladimir Motin; Luis M de la Maza; Ellena M Peterson
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

8.  Real-time PCR for Chlamydia pneumoniae utilizing the Roche Lightcycler and a 16S rRNA gene target.

Authors:  Justin Hardick; Nancy Maldeis; Mellisa Theodore; Billie Jo Wood; Samuel Yang; Shin Lin; Thomas Quinn; Charlotte Gaydos
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

9.  Immune response to chlamydial 60-kilodalton heat shock protein in tears from Nepali trachoma patients.

Authors:  T Hessel; S P Dhital; R Plank; D Dean
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

10.  Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model.

Authors:  Ignatius W Fong; Brian Chiu; Esther Viira; Dan Jang; James B Mahony
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.